文献速递前列腺癌

寡进展性去势抵抗性前列腺癌的进展导向治疗:前瞻性单臂2期MEDCARE试验最终结果

Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial.
PubMed 文献 · Eur Urol Oncol · 2024-04-25

MEDCARE是一项前瞻性单臂非随机2期试验,纳入20例寡进展性转移性去势抵抗性前列腺癌(mCRPC)患者,在继续原有全身治疗的同时对38个寡进展病灶行进展导向治疗(PDT)。中位随访28个月时中位无-next线全身治疗生存期(NEST-FS)为17个月,2年NEST-FS率35%,2年前列腺癌特异性生存率80%、总生存率70%,2年局部控制率95%,无患者出现早期或晚期≥3级毒性;对18F-PSMA PET/CT上全部可见病灶行PDT者NEST-FS更长(30 vs 13个月,p=0.002)。

要点

  • 寡进展性mCRPC患者行PDT并继续原全身治疗,中位NEST-FS为17个月,2年NEST-FS率35%。
  • 中位前列腺癌特异性生存期与中位总生存期均未达到,2年分别为80%和70%。
  • 无患者出现早期或晚期≥3级毒性,2年局部控制率95%。

核心结论

  • 该单中心单臂2期试验显示,对寡进展性mCRPC行PDT的中位NEST-FS为17个月,且无任何早期或晚期≥3级毒性。

研究设计与样本

  • MEDCARE为前瞻性、单臂、非随机2期试验,纳入寡进展性mCRPC患者,行PDT同时继续原有全身治疗,主要终点为NEST-FS。

主要发现

  • 20例患者针对38个寡进展病灶接受PDT,中位随访28个月时中位NEST-FS为17个月,2年NEST-FS率为35%。
  • 中位前列腺癌特异性生存期与中位总生存期均未达到,2年前列腺癌特异性生存率和总生存率分别为80%和70%。
  • 2年局部控制率为95%,无患者出现早期或晚期≥3级毒性。
  • 对18F-PSMA PET/CT上全部可见病灶行PDT的患者NEST-FS更长(30 vs 13个月;p=0.002)。

局限性

  • 原文写明该试验为单中心、单臂2期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Next-line systemic treatment (NEST) is the standard of care for patients presenting with progressive metastatic castration-resistant prostate cancer (mCRPC). Progression-directed therapy (PDT), defined as a lesion-directed approach in patients with a limited number of progressive and/or new lesions, could postpone the need for NEST in these patients with so-called oligoprogressive mCRPC. Our aim was to investigate the feasibility of postponing NEST initiation in oligoprogressive mCRPC by using PDT. METHODS: MEDCARE was a prospective, single-arm, nonrandomized phase 2 trial. Eligible patients had oligoprogressive mCRPC and were treated with PDT while their ongoing systemic therapy was continued. The primary endpoint was NEST-free survival (NEST-FS). Secondary endpoints were prostate-specific antigen response, clinical progression-free survival (cPFS), prostate cancer-specific survival (PCSS), overall survival (OS), and PDT-induced toxicity. KEY FINDINGS AND LIMITATIONS: Twenty patients underwent PDT for 38 oligoprogressive lesions. At median follow-up of 28 mo, median NEST-FS was 17 mo and the 2-yr NEST-FS rate was 35%. Median PCSS and median OS were not reached. The PCSS and OS rates at 2 yr were 80% and 70%, respectively. The 2-yr local control rate was 95%. No patient experienced early or late grade ≥3 toxicity. NEST-FS was longer for patients who received PDT to all lesions visible on 18F-PSMA positron emission tomography/computed tomography (30 vs 13 mo; p = 0.002). CONCLUSIONS AND CLINICAL IMPLICATIONS: This single-center, single-arm, phase 2 trial demonstrated that PDT in oligoprogressive mCRPC resulted in median NEST-FS of 17 mo without any early or late grade ≥3 toxicity. PATIENT SUMMARY: For patients with metastatic prostate cancer no longer responding to hormone therapy, we investigated radiotherapy targeted at progressive cancer lesions while continuing their ongoing systemic treatment. The results show that this targeted therapy had very low toxicity and delayed the need to start a new line of systemic treatment by 17 months.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Rans K, Joniau S, Berghen C, et al. Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial. Eur Urol Oncol. 2024. PMID: 38664137. doi:10.1016/j.euo.2024.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。